![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » ICOS, Caprion Pharmaceuticals Enter Into Joint Development Collaboration
ICOS, Caprion Pharmaceuticals Enter Into Joint Development Collaboration
April 4, 2005
ICOS and Caprion Pharmaceuticals have entered into an agreement for the joint development of therapeutic antibodies for the treatment of cancer.
The collaboration seeks to accelerate the development of new therapeutic antibodies, providing both parties with promising candidates for independent and joint development. Caprion will contribute a selection of proprietary antibody targets and perform certain target characterization activities for the collaboration. ICOS will be responsible for target validation and preclinical development of therapeutic antibodies.
Each company will select a predetermined number of promising antibody candidates for independent development. The terms of the agreement include an up front payment and license fees to Caprion, as well as reciprocal milestone payments that are contingent upon the successful completion of milestones by each company, and reciprocal royalty payments. Additionally, the agreement allows for Caprion and ICOS to co-develop and co-promote certain products developed under the collaboration in the event that ICOS exercises an opt-in provision.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
21Oct